Profil
Stephen M.
Kaufhold is currently the Treasurer at Vitae Pharmaceuticals LLC since 2016.
Prior to this, he was the Treasurer at Allergan GI Corp.
and the Chief Financial Officer at Tobira Therapeutics, Inc.
Postes actifs de Stephen M. Kaufhold
Sociétés | Poste | Début |
---|---|---|
VITAE PHARMACEUTICALS INC | Treasurer | 25/10/2016 |
Anciens postes connus de Stephen M. Kaufhold
Sociétés | Poste | Fin |
---|---|---|
Allergan GI Corp.
Allergan GI Corp. BiotechnologyHealth Technology Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ. | Treasurer | - |
TOBIRA THERAPEUTICS INC | Directeur Financier/CFO | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 3 |
---|---|
Vitae Pharmaceuticals LLC
Vitae Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vitae Pharmaceuticals LLC is a clinical-stage bio-pharmaceutical company, which engages in discovering and developing novel, small molecule drugs for diseases, including chronic kidney disease, diabetes and Alzheimer's disease, and autoimmune disorders, acute coronary syndrome, and immuno-oncology. The company was founded by John J. Baldwin, Bartosz A. Grzybowski, George M. Whitesides, and Eugene Shakhnovich on May 21, 2001 and is headquartered in Fort Washington, PA. | Health Technology |
Tobira Therapeutics, Inc.
Tobira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company was founded on September 11, 2006 and is headquartered in Madison, NJ. | Health Technology |
Allergan GI Corp.
Allergan GI Corp. BiotechnologyHealth Technology Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ. | Health Technology |